Evaluation of Hepatic Function Using Gd-EOB-DTPA Enhanced Liver Magnetic Resonance Imaging
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Liver function assessed by hepatocyte fraction
研究概览
简要总结
Liver function is a key factor that can help predict the clinical outcome in patients with cirrhosis. Traditionally, liver function was measured using either indocyanine green (ICG) or other radionucleotides. Recently, gadoxetic acid has been reported to show liver function in several studies. There have been several approaches to measure liver function using gadoxetic acid, and hepatocyte fraction is one of the promising methods. Since gadoxetic acid enhanced liver MRI is clinically used world widely, it would be valuable if we can measure liver function using hepatocyte fraction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with chronic liver disease or liver cirrhosis
- •clinically scheduled for gadoxetic acid enhanced liver MRI
- •signed informed consent
排除标准
- •under 18 years
- •transarterial chemoembolization, radiation therapy for liver or bile duct within 2 weeks
- •systemic chemotherapy within 6 weeks
- •any contraindication for contrast enhanced MRI
- •hepatic iron deposition at prior imaging
- •bile duct obstruction
研究组 & 干预措施
CLD and LC
Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
干预措施: gadoxetic acid enhanced liver MRI (Drug)
CLD and LC
Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
干预措施: ICG R15 (Drug)
结局指标
主要结局
Liver function assessed by hepatocyte fraction
时间窗: 1 month after MRI
hepatocyte fraction obtained by T1 map sequence
次要结局
- Hepatocyte uptake rate(1 month after MRI)
- Liver function assessed by ICG R15 test(3 days after MRI)
研究者
Jeong Min Lee
Professor
Seoul National University Hospital